-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-507153-16-00
5
2020-11-18
Higher-Risk Myelodysplastic Syndrome
-
2023-504828-25-00
9
2020-11-16
Chronic Lymphocytic Leukemia
-
2023-504805-35-00
9
2020-10-22
Lymphoma of B-cell origin
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2023-503421-19-00
5
2020-08-26
Urothelial cancer
-
2023-507419-37-00
5
2020-06-25
Plasma cell myeloma
-
2024-514592-17-00
4
2020-06-16
chronic myeloid leukemia
-
2023-510537-28-00
5
2020-05-15
Multiple Myeloma
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2023-505624-56-00
5
2019-08-07
Relapsing Remitting Multiple Sclerosis (RRMS)
-
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2024-511781-37-00
4
2019-04-16
YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi